Bariatric Surgery
3
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbVieBotulinum toxin pyloroplasty
Prevail TherapeuticsDuloxetine
Aardvark TherapeuticsARD-101
Clinical Trials (3)
Total enrollment: 116 patients across 3 trials
Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy
Start: Jan 2019Est. completion: Nov 202284 patients
Phase 4Completed
Effects of Gastric Bypass on Blood Levels of Duloxetine
Start: Sep 2009Est. completion: Nov 201220 patients
Phase 3Completed
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
Start: Mar 2022Est. completion: Feb 202312 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.